“Heart failure is a disease with a low survival rate, and the emergence of new treatment options has great significance. Posiga has shown additional clinical benefits to the existing standard treatment for heart failure through clinical studies. If the results are applied to the actual treatment environment, domestic heart failure patients have great significance. It is expected to make a great contribution to improving the survival rate of
Choi Dong-ju, chairman of the Korean Heart Failure Association (Seoul National University Bundang Hospital, Department of Cardiology) said at a press conference to commemorate the expansion of indications for heart failure treatment of’Posiga (ingredient name Dapagliflozin)’ held online by AstraZeneca Korea.
The SGLT-2 inhibitor’Posiga’, which has been widely used as a treatment for type 2 diabetes, was approved by the Ministry of Food and Drug Safety on the 22nd of last month to treat chronic heart failure patients with reduced left ventricular contractile function. It has been reborn as a treatment for heart failure with or without diabetes.
On this day, the press conference was held in a way that Chairman Dong-ju Choi was the chairman, and three experts in charge of research, academic, and general affairs directors of the Korean Heart Failure Association held relay lectures and discussions.
“As fatal and costly as cancer, heart failure needs new treatment options, lower rates of death and hospitalization and lower medical costs.”
Jin-oh Choi, who gave the first presentation on the subject of’Introduction of Heart Failure Diseases and Treatment Goals’ (Sungkyunkwan Medical University, Department of Cardiology, Samsung Medical Center), pinpointed the current situation where the prevalence of heart failure and medical costs in Korea are constantly increasing.
Director Choi Jin-oh said, “Heart failure is a disease in which more than half of patients die within 5 years despite standard treatment, and the prognosis is worse than some cancers.” “Not only the patient’s quality of life is degraded due to symptoms such as shortness of breath and difficulty breathing, but also frequent “It is a disease that puts a great burden on patients’ families due to the burden of medical expenses caused by hospitalization.”
Director Choi Jin-oh said, “As Korea enters an aging society, the number of heart failure patients continues to increase. Therefore, efforts to further reduce death and hospitalization rates due to heart failure and to reduce medical expenses are necessary.”
“Forsyga Demonstrates Additional Clinical Benefits for Patients Already on Standard Care for Heart Failure”
As the second speaker, Sung-Hoon Choi, Academic Director, Department of Cardiology, Gangnam Sacred Heart Hospital, Hallym University, explained the efficacy and safety of’Possiga’ in treating heart failure, which was examined by the DAPA-HF study.
Director Sung-Hoon Choi said, “Forcega confirmed the benefits of heart failure hospitalization and cardiovascular death prevention in a DECLARE study of type 2 diabetes patients, and in the DAPA-HF study, patients with chronic heart failure with decreased left ventricular systolic function regardless of diabetes. “It reduced death from cardiovascular disease or worsening heart failure.”
“In the DAPA-HF study, Posiga reduced the risk of deteriorating heart failure and death from cardiovascular disease in patients already receiving standard heart failure treatment by 26%.” “Existing standard treatments generally have a 30% reduction effect. However, Posiga emphasized that the most significant part of this study is that it showed more clinical benefits in addition to that.
“Based on this, the 2019 European Heart Association/European Diabetes Association guidelines first recommended SGLT-2 inhibitors in type 2 diabetes patients with cardiovascular risk, and SGLT-2 inhibitors were added as recommended drugs for heart failure patients. “In 2021, the American Diabetes Association also recommended SGLT-2 inhibitors after metformin in the high-risk group of type 2 diabetes through guidelines, and the American Heart Association also recommended SGLT-2 inhibitors as a second-stage drug after standard treatment. “He said.
Director Choi Seong-hoon added, “Now, SGLT-2 inhibitors have established themselves as heart drugs, not diabetes drugs, and this will bring benefits not only to patients with chronic heart failure but also to society as a whole.”
“Deterioration of renal function is a major cause of increased risk of hospitalization and death for heart failure. It is important to control chronic kidney disease, a comorbid disease in heart failure patients.”
Eung-ju Kim (Cardiovascular Center, Guro Hospital, Korea University), who gave the last presentation on the subject of’Management of Concomitant Diseases in Heart Failure Patients’, based on the renal benefits found in Posiga’s clinical trial, Posiga in patients with major comorbidities And the clinical benefits of
According to Director Kim Eung-ju, Posiga has a glomerular filtration rate (eGFR) of 60 mL/min/1.73 m in the DECLARE study.2 Renal complex variable (eGFR decreased by at least 40%, 60mL/min/1.73m) in patients with type 2 diabetes2 It showed an advantage of lowering sustained decrease, death from end-stage renal failure or kidney disease) by 47%.
In addition, eGFR 30 mL/min/1.73m in DAPA-HF studies2 In patients with chronic heart failure with decreased left ventricular systolic function, the renal complex variable (eGFR continued to decrease by at least 50%, death from end-stage renal failure or kidney disease) tended to decrease to 29%.
Director Kim Eung-ju said, “As the kidney function worsens, the risk of hospitalization and death from heart failure increases in patients with heart failure,” he said. “Chronic kidney disease contributes to heart failure death by 41%, so it is important to control it well and delay the progression. In terms of disease management, it is good to check kidney-related data in cardiology.”